Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR mRNA–Overexpressing Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial
JAMA Oncol 2024 Sep 19;[EPub Ahead of Print], RF Sweis, P Gajate, R Morales-Barrera, JL Lee, A Necchi, F de Braud, N Penel, V Grünwald, M Maruzzo, J Meran, TC Ishida, W Bao, Y Zhou, P Ellinghaus, JE RosenbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.